Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
| Autor: | Yoshimichi Sai, Morihiro Okada, Kenji D. Furukawa, Masae Okada, Kiminori Ohyama, Jun Nishigami, Tsutomu Shimada, Naoto Yamaaki |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Insulin degludec
medicine.medical_specialty HbA1c endocrine system diseases Pharmacology (nursing) DTR-QOL Internal medicine Diabetes mellitus Medicine Pharmacology (medical) Glargine BOT Glycemic QOL Type 1 diabetes business.industry Insulin glargine Type 2 Diabetes Mellitus nutritional and metabolic diseases medicine.disease Regimen Endocrinology Basal (medicine) business Degludec Detemir Research Article medicine.drug |
| Zdroj: | Journal of Pharmaceutical Health Care and Sciences |
| ISSN: | 2055-0294 |
| DOI: | 10.1186/s40780-015-0027-2 |
| Popis: | Background Maintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes mellitus. Recently introduced insulin degludec has the longest duration of action among basal insulin formulations. The purpose of this study was to assess changes in quality of life (QOL) associated with switching the basal insulin regimen to degludec in patients with type 1 and type 2 diabetes mellitus. Methods This 24-week open-label intervention study included type 1 (n = 10) and type 2 (n = 20) diabetes mellitus patients, with adequately controlled hemoglobin A1c (HbA1c), who had received insulin glargine or detemir for at least 6 months. The primary outcome was change of QOL from baseline, as assessed by the Diabetes Therapy-Related QOL (DTR-QOL) application, after switching from glargine or detemir to degludec. HbA1c and other parameters were also assessed as secondary outcomes. Results QOL and HbA1c in patients with type 1 diabetes mellitus were unchanged during this study. In patients with type 2 diabetes mellitus, HbA1c did not change, but total DTR-QOL score was significantly improved from baseline after switching to degludec. The DTR-QOL Factor 2, “Anxiety and dissatisfaction with treatment”, was significantly improved in patients with type 2 diabetes mellitus and especially in the subgroup receiving basal supported oral therapy (BOT). Conclusions Switching of the basal insulin regimen from glargine or detemir to degludec significantly improved the QOL of patients with type 2 diabetes mellitus who were receiving BOT, by reducing mental stress or anxiety about their treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|